PURPOSE: Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, their clinical progress has been hampered by low bioavailability and off-target toxicities. MATERIALS AND METHODS: We characterized the radiosensitizing activity of CCT244747, the first orally bioavailable Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and monitored the effect of combining CCT244747 with radiation both in in vitro and in vivo models. RESULTS: CCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth delay in cancer xenograft models associated with a survival benefit. Radiosensitization was elicited by abrogation of the radiation-induced G2 arrest and premature entry into mitosis. CONCLUSIONS: CCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It radiosensitizes tumour cell lines and represents a new therapy for clinical application in combination with radiotherapy.
PURPOSE: Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, their clinical progress has been hampered by low bioavailability and off-target toxicities. MATERIALS AND METHODS: We characterized the radiosensitizing activity of CCT244747, the first orally bioavailable Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and monitored the effect of combining CCT244747 with radiation both in in vitro and in vivo models. RESULTS: CCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth delay in cancer xenograft models associated with a survival benefit. Radiosensitization was elicited by abrogation of the radiation-induced G2 arrest and premature entry into mitosis. CONCLUSIONS: CCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It radiosensitizes tumour cell lines and represents a new therapy for clinical application in combination with radiotherapy.
Authors: E A Sausville; S G Arbuck; R Messmann; D Headlee; K S Bauer; R M Lush; A Murgo; W D Figg; T Lahusen; S Jaken; X Jing ; M Roberge; E Fuse; T Kuwabara; A M Senderowicz Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Leslie A Parsels; Yushen Qian; Daria M Tanska; Marisa Gross; Lili Zhao; Maria C Hassan; Sankari Arumugarajah; Joshua D Parsels; Linda Hylander-Gans; Diane M Simeone; Deborah Morosini; Jeffrey L Brown; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan Journal: Clin Cancer Res Date: 2011-04-11 Impact factor: 12.531
Authors: James B Mitchell; Rajani Choudhuri; Kristin Fabre; Anastasia L Sowers; Deborah Citrin; Sonya D Zabludoff; John A Cook Journal: Clin Cancer Res Date: 2010-03-16 Impact factor: 12.531
Authors: Nicholas D James; Syed A Hussain; Emma Hall; Peter Jenkins; Jean Tremlett; Christine Rawlings; Malcolm Crundwell; Bruce Sizer; Thiagarajan Sreenivasan; Carey Hendron; Rebecca Lewis; Rachel Waters; Robert A Huddart Journal: N Engl J Med Date: 2012-04-19 Impact factor: 91.245
Authors: Mike I Walton; Paul D Eve; Angela Hayes; Melanie R Valenti; Alexis K De Haven Brandon; Gary Box; Albert Hallsworth; Elizabeth L Smith; Kathy J Boxall; Michael Lainchbury; Thomas P Matthews; Yann Jamin; Simon P Robinson; G Wynne Aherne; John C Reader; Louis Chesler; Florence I Raynaud; Suzanne A Eccles; Ian Collins; Michelle D Garrett Journal: Clin Cancer Res Date: 2012-08-28 Impact factor: 12.531
Authors: Hind Hafsi; Magnus T Dillon; Holly E Barker; Joan N Kyula; Ulrike Schick; James T Paget; Henry G Smith; Malin Pedersen; Martin McLaughlin; Kevin J Harrington Journal: Front Oncol Date: 2018-07-13 Impact factor: 6.244
Authors: Ina Patties; Sonja Kallendrusch; Lisa Böhme; Eva Kendzia; Henry Oppermann; Frank Gaunitz; Rolf-Dieter Kortmann; Annegret Glasow Journal: J Exp Clin Cancer Res Date: 2019-10-21